+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

From
From
From
Global CD19 Antibody Market & Clinical Pipeline Outlook 2028 - Product Thumbnail Image

Global CD19 Antibody Market & Clinical Pipeline Outlook 2028

  • Report
  • October 2023
  • 420 Pages
  • Global
From
Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 - Product Thumbnail Image

Global CD19 Antibody Market and Clinical Pipeline Outlook 2028

  • Report
  • October 2023
  • 420 Pages
  • Global
From
From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • September 2023
  • 249 Pages
  • Global
From
Bi-Specific MAbS Global Market Report 2024 - Product Thumbnail Image

Bi-Specific MAbS Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
CAR-T Therapy Global Market Report 2024 - Product Thumbnail Image

CAR-T Therapy Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Blood Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Blood Cancer Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
Cellular Immunotherapy Global Market Report 2024 - Product Thumbnail Image

Cellular Immunotherapy Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
Drugs for Immunotherapy Global Market Report 2024 - Product Thumbnail Image

Drugs for Immunotherapy Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Cancer Immunotherapy Global Market Report 2024 - Product Thumbnail Image

Cancer Immunotherapy Global Market Report 2024

  • Report
  • December 2023
  • 200 Pages
  • Global
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more